Balyasny Asset Management LLC Grifols Sa Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.14 - $9.29 $4.36 Million - $5.67 Million	-610,046 Reduced 68.77%	277,032 $2.54 Million
Q1 2023 May 15, 2023	SELL	$6.65 - $10.69 $2.46 Million - $3.96 Million	-370,465 Reduced 29.46%	887,078 $6.54 Million
Q4 2022 Feb 14, 2023	BUY	$5.96 - $8.53 $3.01 Million - $4.31 Million	504,949 Added 67.09%	1,257,543 $10.7 Million
Q3 2022 Nov 14, 2022	BUY	$5.95 - $14.3 $4.48 Million - $10.8 Million	752,594 New	752,594 $4.64 Million
Q4 2020 Feb 16, 2021	SELL	$16.86 - $19.67 $2.58 Million - $3.01 Million	-153,258 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$15.4 - $20.16 $2.36 Million - $3.09 Million	153,258 New	153,258 $2.66 Million
Q2 2020 Aug 14, 2020	SELL	$18.24 - $21.45 $1.07 Million - $1.26 Million	-58,551 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$16.28 - $25.63 $953,210 - $1.5 Million	58,551 New	58,551 $1.18 Million
Q3 2019 Nov 14, 2019	SELL	$19.85 - $22.76 $2.27 Million - $2.6 Million	-114,126 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$17.59 - $21.1 $2.01 Million - $2.41 Million	114,126 New	114,126 $2.41 Million

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.31B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.